Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population

Journal of the American Academy of Dermatology

Volumn 76, Issue 4, 2017, Pages 632-638

  Asgari, Maryam M ^a,b   Ray, G Thomas ^a   Geier, Jamie L ^c   Quesenberry, Charles P ^a  

^a DIVISION OF RESEARCH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c PFIZER INC   (United States)

Author keywords

basal cell carcinoma; biologics; cancer; cutaneous squamous cell carcinoma; epidemiology; nonmelanoma skin cancer; psoriasis; tumor necrosis factor alfa

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; ETRETIN; GOLIMUMAB; HYDROXYUREA; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; SALAZOSULFAPYRIDINE; TIOGUANINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; AGE; AGED; ARTICLE; BASAL CELL CARCINOMA; BLACK PERSON; BODY MASS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HISPANIC; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MELANOMA; MIDDLE AGED; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SENSITIVITY ANALYSIS; SKIN CARCINOMA; ULTRAVIOLET PHOTOTHERAPY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CALIFORNIA; CARCINOMA, SQUAMOUS CELL; COMORBIDITY; HEALTH INSURANCE; IMMUNOCOMPROMISED PATIENT; INCIDENCE; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; PROPORTIONAL HAZARDS MODEL; SKIN NEOPLASMS; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; CALIFORNIA; CARCINOMA, SQUAMOUS CELL; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; PROPORTIONAL HAZARDS MODELS; PSORIASIS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; ULTRAVIOLET THERAPY; YOUNG ADULT;

EID: 85011277268     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.10.006     Document Type: Article

References (26)

1. 1 Rachakonda, T.D., Schupp, C.W., Armstrong, A.W., Psoriasis prevalence among adults in the United States. J Am Acad Dermatology 70 (2014), 512–516.
2. 2 National Psoriasis Foundation. About psoriasis. Available from: URL: http://www.psoriasis.org/about-psoriasis/treatments/severity. Accessed March 15, 2015.
3. 3 Dubreuil, M., Rho, Y.H., Man, A., et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology 53 (2014), 346–352.
4. 4 Horreau, C., Pouplard, C., Brenaut, E., et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 27 Suppl 3 (2013), 12–29.
5. 5 Kothary, N., Diak, I.L., Brinker, A., et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65 (2011), 546–551.
6. 6 Asgari, M.M., Wu, J.J., Gelfand, J.M., et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug saf 22 (2013), 842–849.
7. 7 Asgari, M.M., Eide, M.J., Warton, E.M., et al. Validation of a large basal cell carcinoma registry. J Registry Manag 40 (2013), 65–69.
8. 8 Balkwill, F., TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25 (2006), 409–416.
9. 9 Larmonier, N., Cathelin, D., Larmonier, C., et al. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res 313 (2007), 2345–2355.
10. 10 Berg, D., Otley, C.C., Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 47 (2002), 1–17 quiz 8-20.
11. 11 Silverberg, M.J., Leyden, W., Warton, E.M., et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 105 (2013), 350–360.
12. 12 Brewer, J.D., Hoverson Schott, A.R., Roenigk, R.K., Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature. Int J Dermatol 50 (2011), 1555–1559.
13. 13 Young, L., Czarnecki, D., The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 53 (2012), 57–60.
14. 14 Simpkin, S., Oakley, A., Multiple eruptive squamous cell carcinoma in a patient with chronic plaque psoriasis on adalimumab. Australas J Dermatol 54 (2013), 55–58.
15. 15 Zitelli, K.B., Zedek, D., Ranganathan, P., et al. Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF-alpha inhibitors and cutaneous carcinoma risk. Cutis 92 (2013), 35–39.
16. 16 Langley, R.G., Papp, K., Gottlieb, A.B., et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 27 (2013), 1252–1261.
17. 17 Gordon, K.B., Papp, K.A., Langley, R.G., et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 66 (2012), 742–751.
18. 18 Bongartz, T., Sutton, A.J., Sweeting, M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006), 2275–2285.
19. 19 Kimball, A.B., Rothman, K.J., Kricorian, G., et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol 72 (2015), 115–122.
20. 20 Kimball, A.B., Schenfeld, J., Accortt, N.A., et al. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br J Dermatol 170 (2014), 366–373.
21. 21 Moran, G.W., Lim, A.W., Bailey, J., et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 38 (2013), 1002–1024.
22. 22 van Lumig, P.P., Menting, S.P., van den Reek, J.M., et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol 29 (2015), 752–760.
23. 23 Paul, C.F., Ho, V.C., McGeown, C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120 (2003), 211–216.
24. 24 Pouplard, C., Brenaut, E., Horreau, C., et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 27 Suppl 3 (2013), 36–46.
25. 25 Moffet, H.H., Adler, N., Schillinger, D., et al. Cohort profile: the Diabetes Study of Northern California (DISTANCE)–objectives and design of a survey follow-up study of social health disparities in a managed care population. Int J Epidemiol 38 (2009), 38–47.
26. 26 Gordon, N., Similarity of the adult Kaiser Permanente membership in northern California to the insured and general population in northern California: statistics from the 2009 California health interview survey. Internal Division of Research report. 2012, Kaiser Permanente Division of Research, Oakland (CA).